M
Mogrify
Transforming the development of life saving cell therapies via the licence of proprietary cell conversions tailored to any therapeutic application
About Mogrify
Mogrify operates in the biotechnology sector, focusing on the development of ex vivo cell therapies and pioneering in vivo reprogramming therapies. The company has developed a proprietary platform that leverages transcriptomic and epigenetic data to identify optimal combinations of transcription factors for converting any cell type into another. This technology is aimed at addressing diseases with high unmet clinical needs by enabling scalable and efficient cell conversions. Mogrify serves pharmaceutical companies, research institutions, and healthcare providers, offering solutions that enhance the development and maintenance of cell therapies. The business model is based on licensing its technology, forming strategic partnerships, and executing royalty-bearing deals. Revenue is generated through upfront payments, milestone payments, and royalties from commercialized therapies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Cambridge, United Kingdom
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 61.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Synthetic Biology, Spinout, Biotech and Pharma, AI Drug Discovery, Techbio, Techbio Drug Discovery, Longevity
- Technology
- Big Data
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2023 | $10M | $85M | Astellas Venture · Ahren Innovation Capital · Jonathan Milner · Parkwalk Advisors | ↗ |
| SERIES AEquity / VC | Sep 2021 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Mogrify is 300 monthly website visits, down 61.5% over the last three months. Mogrify's team declined 21.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Ahren Innovation Capital
24Haymarket
Series A5 investors entered at this stage
University of Bristol Enterprise Fund
Parkwalk Advisors
Dr Darrin M Disley OBE
Jonathan Milner
Astellas Venture
Other known investors3 additional known investors
Monash University
University of Bristol
D+V Nachfolge
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mogrify on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mogrify’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.